Translumina startet die globale randomisierte kontrollierte Studie „SPARX", um die Evidenzbasis für medikamentenbeschichtete Ballons bei komplexen Koronarerkrankungen zu erweitern

Trial Startdrug-coated balloonNeutral

AI Analysis

Summary

Translumina has officially launched the global randomized controlled trial SPARX to expand the evidence base for drug-coated balloons in the treatment of complex coronary artery disease.

Clinical Trial Data

Importance:3/10

Sentiment:

0.00

clinical trialrandomized controlled trialdrug-coated ballooncoronary artery diseasecardiology

Read the original article

Published by PR Newswire Clinical Trials on October 13, 2026 4:05 AM

Read Original